Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04246086 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
A Phase 1 study of Follicular Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 1
- Development phase
- 237
- Enrollment target
- 20
- Study locations
NCT04246086: Active Phase 1 study of Follicular Lymphoma, sponsored by Hoffmann-La Roche.
NCT04246086 is a Phase 1 study of Follicular Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 237 participants, above the 132-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04246086, a Phase 1 study of Follicular Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 237 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Tocilizumab
- DRUG Mosunetuzumab (IV)
- DRUG Mosunetuzumab (SC)
Study Locations (20)
Other
- The First Hospital of Jilin University - Changchun
- West China Hospital, Sichuan University - Chengdu
- Fudan University Shanghai Cancer Center - Shanghai
- Tianjin Medical University Cancer Institute & Hospital - Tianjing
- The First Affiliated Hospital of Xiamen University - Xiamen
- Centre Hospitalier Lyon Sud - Pierre-Bénite
- CHU Rennes - Hopital Pontchaillou - Rennes
Ohio
- Fairview Hospital - Cleveland
- Cleveland Clinic - Cleveland
- Hillcrest Hospital - Mayfield Heights
Tennessee
- Tennessee Oncology;Chattanooga Oncology & Hematology Associates - Chattanooga
- Tennessee Oncology PLLC - Franklin - Franklin
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami Miller School of Medicine - Miami
Kentucky
- Norton Cancer Institute - St. Matthews - Louisville
Louisiana
- Mary Bird Perkins Cancer Ctr - Baton Rouge
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2030-09-06 |
| Phase | Phase 1 |
What the registry record for NCT04246086 still lists
NCT04246086 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, above the 132-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (80% higher).
The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Lenalidomide is the first listed.
NCT04246086 names 20 study sites across 11 states, led by Other, Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04246086 about?
NCT04246086 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma". This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of ...
What is the current status of trial NCT04246086?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 237 participants. The study started on 2020-08-12. Estimated completion is 2030-09-06.
What conditions does trial NCT04246086 study?
This clinical trial studies the following conditions: Follicular Lymphoma.
What interventions are being tested in trial NCT04246086?
The interventions under investigation include: Lenalidomide (DRUG), Tocilizumab (DRUG), Mosunetuzumab (IV) (DRUG), Mosunetuzumab (SC) (DRUG).
Who is sponsoring clinical trial NCT04246086?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04246086 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04246086's enrollment target sits among peer trials
237 14th of 89 higher than 76 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI